跳转至内容
Merck

SML2655

Sigma-Aldrich

Reparixin

≥98% (HPLC)

别名:

αR-methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-benzeneacetamide, (R)-(-)-N-2-[(4-Isobutylphenyl)propionyl]methanesulfonamide, DF 1681Y, Repertaxin

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C14H21NO3S
分子量:
283.39
MDL编号:
UNSPSC代码:
51111800
NACRES:
NA.77
价格与库存信息目前不能提供

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D -80 to -90°, c = 1.0 in ethanol

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

[S](=O)(=O)(NC(=O)C(C)c1ccc(cc1)CC(C)C)C

InChI

1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)

InChI key

KQDRVXQXKZXMHP-UHFFFAOYSA-N

生化/生理作用

Noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2
Reparixin is a noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2 with IC50 values of 1 nM for CXCR1 and 100 nM for CXCR2. It is believed to prevent receptor signaling by locking CXCR1/R2 in an inactive conformation. Reparixin has been studied to prevent ischaemia-reperfusion injury and inflammation and is clinical trials for triple negative breast cancer and to prevent injury occurring after pancreatic islet transplantation.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

N C Bergenhem et al.
Biochemical genetics, 30(5-6), 279-287 (1992-06-01)
Two, electrophoretically distinct, forms of carbonic anhydrase I (CA Ia and CA Ib) are found at high polymorphic frequencies in red cells of natural populations of pigtail macaques, Macaca nemestrina, from southeast Asia. By use of the polymerase chain reaction
P Opfermann et al.
Clinical and experimental immunology, 180(1), 131-142 (2014-11-18)
Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischaemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce. The aim of this double-blinded, placebo-controlled pilot study was to evaluate the safety and efficacy
Anne F Schott et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(18), 5358-5365 (2017-05-26)
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational allosteric inhibitor of chemokine receptors 1 and 2 (CXCR1/2), and demonstrates activity against BCSCs in human breast

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持